Cano Health, Inc.
CANOQ
OTC PK
Weiss Ratings | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Very Weak | |||
Risk Grade | E+ | |||
Reward Grade | E | |||
Rating Factors | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Weak | |||
Total Return Index | Very Weak | |||
Volatility Index | Very Weak | |||
Beta / Standard Deviation | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | -1.25 | |||
Price History | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 20.00% | |||
30-Day Total Return | -14.29% | |||
60-Day Total Return | -7.69% | |||
90-Day Total Return | -40.00% | |||
Year to Date Total Return | -95.41% | |||
1-Year Total Return | -99.82% | |||
2-Year Total Return | -99.95% | |||
3-Year Total Return | -99.98% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -99.86% | |||
52-Week Low % Change | 140.00% | |||
Price | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $174.00 | |||
52-Week Low Price | $0.10 | |||
52-Week Low Price (Date) | Feb 12, 2024 | |||
52-Week High Price (Date) | Aug 04, 2023 | |||
Valuation | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 1.14M | |||
Enterprise Value | -37.54M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -300.34 | |||
Earnings Per Share Growth | 201.22% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 0.00 | |||
Price/Book (Q) | 0.00 | |||
Enterprise Value/Revenue (TTM) | -0.01 | |||
Price | $0.24 | |||
Enterprise Value/EBITDA (TTM) | 0.09 | |||
Enterprise Value/EBIT | 0.07 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 5.25M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 855 208 8389 | |||
Address | 9725 NW 117th Avenue Miami, FL 33178 | |||
Website | canohealth.com | |||
Country | United States | |||
Year Founded | 2009 | |||
Profitability | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -17.67% | |||
Profit Margin | -33.22% | |||
Management Effectiveness | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -21.84% | |||
Return on Equity | -- | |||
Income Statement | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 2.96B | |||
Total Revenue (TTM) | 2.96B | |||
Revenue Per Share | $563.02 | |||
Gross Profit (TTM) | -13.30M | |||
EBITDA (TTM) | -425.15M | |||
EBIT (TTM) | -522.38M | |||
Net Income (TTM) | -981.97M | |||
Net Income Avl. to Common (TTM) | -981.97M | |||
Total Revenue Growth (Q YOY) | -21.05% | |||
Earnings Growth (Q YOY) | -689.31% | |||
EPS Diluted (TTM) | -300.34 | |||
EPS Diluted Growth (Q YOY) | -657.04% | |||
Balance Sheet | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 179.39M | |||
Cash Per Share (Q) | $34.18 | |||
Total Current Assets (Q) | 255.08M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | -1.01B | |||
Current Ratio (Q) | 0.955 | |||
Book Value Per Share (Q) | -$187.65 | |||
Total Assets (Q) | 1.05B | |||
Total Current Liabilities (Q) | 267.00M | |||
Total Debt (Q) | 267.70M | |||
Total Liabilities (Q) | 2.05B | |||
Total Common Equity (Q) | -882.22M | |||
Cash Flow | CANOQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 24.30M | |||
Cash from Financing (TTM) | 257.22M | |||
Net Change in Cash (TTM) | 133.11M | |||
Levered Free Cash Flow (TTM) | -223.75M | |||
Cash from Operations (TTM) | -148.41M | |||